A5073752190- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- CAR-T cell therapy research
- PI3K/AKT/mTOR signaling in cancer
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Multiple and Secondary Primary Cancers
- Chronic Lymphocytic Leukemia Research
- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
- Melanoma and MAPK Pathways
- Lung Cancer Treatments and Mutations
- Chemotherapy-induced cardiotoxicity and mitigation
- RNA Interference and Gene Delivery
- Virus-based gene therapy research
- Cutaneous Melanoma Detection and Management
- Prostate Cancer Treatment and Research
- Breast Cancer Treatment Studies
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
Jagiellonian University
2016-2025
Krakow Cardiovascular Research Institute
2016-2025
University of Warmia and Mazury in Olsztyn
2009-2024
Szpital Uniwersytecki w Krakowie
2016-2024
GlaxoSmithKline (Poland)
2023
Lublin Oncology Center
2011-2023
Cracow University of Technology
2020-2023
Lodz University of Technology
2021-2022
Ministry of Health
2019-2021
The Maria Sklodowska-Curie National Research Institute of Oncology
2014-2018
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 ). METHODS Post-/pre-/perimenopausal women, or men, age 18 years older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly...
1023 Background: Chemotherapy with immune checkpoint inhibitors can improve outcomes vs chemotherapy alone in patients (pts) metastatic TNBC; however, many still have poor clinical outcomes. BEGONIA is an ongoing 2 part, multicenter, multiarm, open-label platform study evaluating safety and efficacy of D (anti–PD-L1)+P D±P combined novel therapies as first-line (1L) treatment for TNBC (NCT03742102). We report initial results from Part 1 Arm 1, D+P, 6, D+T-DXd, antibody-drug conjugate...
Abstract Background: Current treatments for mCRPC include the androgen receptor antagonist enzalutamide (enza). Enza may enhance IFNγ signaling and sensitize tumor cells to immune-mediated cell killing, making it a candidate combinations with PD-L1/PD-1 inhibitors. Responses have been observed in patients (pts) receiving inhibitor or without enza. Therefore, atezolizumab (atezo), humanized anti-PD-L1 monoclonal antibody that inhibits interaction between PD-L1 its receptors, is being examined...
Abstract Background: Patients with HR− advanced/metastatic breast cancer (a/mBC) a low level of HER2 (immunohistochemistry [IHC] score 1+ or IHC 2+ and negative in situ hybridization [ISH]) have poor prognosis. Combining 1L chemotherapy immune checkpoint inhibitors can modestly improve outcomes vs alone, but treatment benefit is largely seen patients PD-L1+ disease. BEGONIA (NCT03742102) an ongoing 2-part, open-label platform study, evaluating safety efficacy D, anti–PD-L1 antibody, combined...
Patients with advanced ovarian cancer (OC) have a detrimental prognosis. The options for systemic treatment of OC in later lines are limited by the availability active therapies and their applicability to often fragile, exhausted patients poor performance status. Metronomic chemotherapy (MC) is concept continuous administration cytotoxic drugs, which characterized multidirectional activity (anti-proliferative, anti-angiogenic, anti-immunosuppressive) low toxicity. We performed retrospective...
Risk communication has been identified as a core competence for guiding public health responses to infectious disease threats. The International Health Regulations (2005) call all countries build capacity and comprehensive understanding of risks before emergency allow systematic coherent communication, response management. Research studies indicate that while outbreak crisis concepts tools have long on the agenda officials, there is still need clarify integrate risk into more standardised...
4565 Background: In DP-02, T-DXd showed robust responses and clinically meaningful survival outcomes in 267 pretreated pts with HER2-expressing solid tumors; the objective response rate (ORR) by investigator (INV) was 37.1% (95% CI 31.3, 43.2). Here we report subgroup analyses bladder cohort (urothelial carcinoma including transitional cell of renal pelvis, ureter, urinary bladder, or urethra), characterize an (OR). Methods: This open-label, Phase 2 study (NCT04482309) evaluated (5.4 mg/kg...
Breast cancer, with 2.3 million new cases and 0.7 deaths every year, represents a great medical challenge worldwide. These numbers confirm that approx. 30% of BC patients will develop an incurable disease requiring life-long, palliative systemic treatment. Endocrine treatment chemotherapy administered in sequential fashion are the basic options advanced ER+/HER2- BC, which is most common type. The palliative, long-term should not only be highly active but also minimally toxic to allow...
Abstract Background: Patients with a/mTNBC have limited treatment options and a poor prognosis (objective response rate [ORR] of 37%, median duration 6.5 months, overall survival 15.5 months for 1L chemotherapy [Rugo, et al. Ann Oncol. 2021 LBA16]). Combining checkpoint inhibitors modestly improves outcomes but only in PD-L1–positive a/mTNBC, emphasizing critical unmet need patients PD-L1–negative disease further improving disease. BEGONIA (NCT03742102) is an ongoing 2-part, open-label...
Patients with human epidermal growth factor receptor (HER)-2+ breast cancer are at particularly high risk for brain metastases; however, the biological basis is not fully understood. Using a novel HER-2 assay, we investigated correlation between quantitative expression in primary cancers and time to metastasis (TTBM) HER-2+ advanced patients treated trastuzumab.The study group included 142 consecutive who were administered trastuzumab-based therapy metastatic cancer. HER-2/neu gene copy...
P95HER2 (p95) is a truncated form of the HER2, which lacks trastuzumab-binding site and contains hyperactive kinase domain. Previously, an optimal clinical cutoff p95 expression for progression-free survival (PFS) overall (OS) was defined using quantitative VeraTag assay (Monogram Biosciences) in training set trastuzumab-treated metastatic breast cancer (MBC) patients.In current study, predictive value established retrospectively validated PFS OS independent series 240 MBC patients from...
Background/Objectives: Bladder cancer is a significant clinical problem with approximately 500,000 new cases worldwide annually. In 25% of cases, disease diagnosed at stage invasion the muscle layer bladder. The current standard approach in this preoperative chemotherapy followed by radical cystectomy. Dose-dense MVAC (ddMVAC), two-day regimen, reference treatment protocol setting. presented study evaluated effectiveness and safety accelerated (aMVAC) chemotherapy-a one-day regimen given...
Background/Objectives: Ectopic Cushing’s syndrome (ECS) is a rare, life-threatening condition caused by uncontrolled ACTH secretion from tumors, most commonly small-cell lung cancer (SCLC). ECS traditionally reported in 1–6% of SCLC cases; however, recent data suggest it may be much higher. This study compares the clinical presentation SCLC-related (ECS-SCLC) with other etiologies and analyzes diagnosis, treatment, outcomes ECS-SCLC. Methods: We retrospectively analyzed records 39 patients...